Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02482311 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
NCT02482311 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 92 participants.
The verdict
NCT02482311, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
Study Summary
This is an open-label, multi-centre, Phase Ib study of AZD1775 designed to assess the safety, tolerability, pharmacokinetics, and anti-tumour activity of AZD1775 monotherapy in patients with advanced solid tumours.
Interventions
- DRUG AZD 1775
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2015-07-01 |
| Est. Completion | 2019-08-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02482311
The ClinicalTrials.gov registry entry for NCT02482311 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD 1775 is the first listed.
NCT02482311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02482311 about?
NCT02482311 is a clinical study titled "Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours". This is an open-label, multi-centre, Phase Ib study of AZD1775 designed to assess the safety, tolerability, pharmacokinetics, and anti-tumour activity of AZD1775 monotherapy in patients with advanced solid tumours.
What is the current status of trial NCT02482311?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2015-07-01. Estimated completion is 2019-08-22.
What interventions are being tested in trial NCT02482311?
The interventions under investigation include: AZD 1775 (DRUG).
Who is sponsoring clinical trial NCT02482311?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.